TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34344706
Drug: OKZ 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 64 mg every 4 weeks
Study: 34605045
Drug: BMS-986263 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986263 (90 mg)
Study: 34605045
Drug: BMS-986263 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986263 (45 mg)
Study: 35065784
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (2000 mg peanut protein per day for 134 weeks)
Study: 34669990
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy
Study: 32641012
Drug: Daily AIH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily AIH (15, 90s episodes at 10.0% O2 with 60s intervals at 20.9% O2)
Study: 32641012
Drug: Daily SHAM
Normalized name: Alberto VO5 Normal With Biotin Daily Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SHAM (15, 90s episodes at 20.9% O2 with 60s intervals at 20.9% O2)
Study: 32641012
Drug: Daily AIH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily AIH + WALK (60-min walking practice)
Study: 32641012
Drug: Daily SHAM
Normalized name: Alberto VO5 Normal With Biotin Daily Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SHAM + WALK (60-min walking practice)
Study: 32641012
Drug: Daily AIH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily AIH and SHAM interventions
Study: 34543890
Drug: Prenatal DHA
Normalized name: Prenatal DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal DHA (400 mg/day)
Study: 33422811
Drug: Metformin users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin users
Study: 32803709
Drug: Pre-probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-probiotic group (PreProBG, n = 16; 200 g/day yogurt plus 10 g/day inulin+oligofructose)
Study: 32803709
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (ProBG, n = 16; 200 g/day yogurt only)
Study: 32920614
Drug: No irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No irrigation after post preparation (G1)
Study: 36604812
Drug: ATI-450 50-mg
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-450 50-mg oral tablets twice daily
Study: 34881361
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (100,000 IU as a bolus dose followed by 20,000 IU per week)
Study: 33617367
Drug: ACCESS intervention
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACCESS intervention (two-semester cognitive-behavioral treatment program)
Study: 34498590
Drug: Chronic anticoagulant
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic anticoagulant therapy
Study: 37966670
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulant
Study: 35395697
Drug: DWP16001 (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 (0.2, 0.5, 1.0, 2.0 or 5.0 mg single dose)
Study: 35395697
Drug: DWP16001 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 (0.1, 0.3, 0.5, 1.0 or 2.0 mg once daily for 15 days)
Study: 33865494
Drug: 7-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day infusion set replacement
Study: 33865494
Drug: 4-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day infusion set replacement
Study: 34409492
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of tranexamic acid (TXA) at incision, three hours post-operatively, and six hours post-operatively
Study: 34409492
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tranexamic acid (TXA)
Study: 34409492
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of tranexamic acid (TXA)
Study: 34260036
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of magnesium citrate
Study: 33636823
Drug: G6PD activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G6PD activity cutoff <7.85 U/g hemoglobin (Hb) for males
Study: 33636823
Drug: G6PD activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G6PD activity cutoff <8.95 U/g Hb for females
Study: 33725780
Drug: Durvalumab (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (maintenance therapy)
Study: 33374147
Drug: Capsaicin analogue
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin analogue (Capsiate) 24 mg (two doses of 12 mg each)
Study: 33682603
Drug: SARS-CoV-2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccines
Study: 35992551
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment and regular nursing for advanced cancer patients
Study: 34851250
Drug: Placebo laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laparoscopic assisted TAP (L‐TAP)
Study: 34851250
Drug: Active L‐TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active L‐TAP
Study: 32826442
Drug: Local creams
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local creams (control group)
Study: 33208640
Drug: Stemless implant
Normalized name: gentian, stemless, whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stemless implant
Study: 33208640
Drug: Stemmed implant
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stemmed implant
Study: 32560734
Drug: Dingkun pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dingkun pill (DKP)
Study: 34583694
Drug: Individual-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-based oral hygiene intervention
Study: 35039035
Drug: Recaticimab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recaticimab (75 mg every 4 weeks, 150 mg every 8 weeks, 300 mg every 12 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks, 450 mg every 12 weeks)
Study: 34496799
Drug: Nifedipine (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (48-hour oral treatment)
Study: 34496799
Drug: Placebo (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (48-hour oral treatment)
Study: 35240576
Drug: Acetaminophen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (20 mg·kg body mass‐1)
Study: 35791320
Drug: CVnCoV vaccine
Normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV vaccine (6 or 12 µg doses)
Study: 35791320
Drug: CVnCoV vaccine
Normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV vaccine (two doses)
Study: 35791320
Drug: CVnCoV vaccine
Normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV vaccine (homologous booster doses)
Study: 39040887
Drug: CVnCoV vaccine
Normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV vaccine
Study: 35791320
Drug: CVnCoV vaccine
Normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV vaccine (two 12 µg doses)
Study: 33822441
Drug: Alcohol (males:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (males: 0.80 g/kg; females: 0.72 g/kg)
Study: 32380746
Drug: 60 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/d goat cheese naturally enriched in n‐3 PUFA and CLA
Study: 32380746
Drug: 60 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/d control goat cheese
Study: 34648533
Drug: Meningococcal B
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal B vaccine (Bexsero, GlaxoSmithKline)
Study: 33650930
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron plus 8 mg dexamethasone
Study: 32234902
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus platinum-based chemotherapy
Study: 35243872
Drug: Intensive-treatment group
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive-treatment group
Study: 33899216
Drug: Electronic point‐of‐care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic point‐of‐care decision support, combination cardiovascular medications (polypills), pharmacy‐based medication adherence program
Study: 35889755
Drug: Curcumin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin treatment in DM + I/R rats
Study: 35889755
Drug: DM (streptozotocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM (streptozotocin, 65 mg/k, single dose, i.v.)
Study: 36484188
Drug: Pricking‐cupping therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking‐cupping therapy
Study: 36484188
Drug: Acupuncture‐cupping therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture‐cupping therapy
Study: 32933955
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine and four courses of SMC SP+AQ
Study: 32933955
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine in year 1 and hepatitis A vaccine in years 2 and 3 with four cycles of SMC SP+AQ
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV)
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV) in LEV-naive patients
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV) in patients with prior LEV use and discontinuation due to insufficient efficacy
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV) in patients with prior LEV use and discontinuation due to AEs
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV) with strong enzyme-inducing antiseizure medications (EiASMs)
Study: 34476770
Drug: Adjunctive Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Brivaracetam (BRV) with sodium channel blockers (SCBs)
Study: 33188886
Drug: pecavaptan 30
Normalized name: Pecavaptan
DrugBank: Pecavaptan (DB16279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pecavaptan 30 mg/d
Study: 33188886
Drug: pecavaptan or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: pecavaptan or diuretics as monotherapy
Study: 33446347
Drug: Well-being intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being intervention derived from Well-Being Therapy (WBT)
Study: 32757999
Drug: Pericapsular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericapsular injection of 30 mL of ropivacaine and 12 mg of morphine
Study: 34843023
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (0.3% and 0.15% HA)
Study: 34068170
Drug: Cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol (450‐500 mg)
Study: 35199973
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of intravenous morphine
Study: 33435475
Drug: Gum Arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum Arabic (GA) 20 g daily for 12 weeks
Study: 33435475
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g pectin)
Study: 34255069
Drug: Trp-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trp-3 (3 g)
Study: 34255069
Drug: Trp-1.5 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trp-1.5 (1.5 g)
Study: 34344121
Drug: Compound wild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound wild chrysanthemum eye masks
Study: 35834777
Drug: Active maintenance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active maintenance olaparib (300 mg twice daily)
Study: 35122549
Drug: Metronidazole adjunctive
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole adjunctive to periodontal surgery
Study: 35122549
Drug: Placebo adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adjunctive to periodontal surgery
Study: 34791813
Drug: DEX 40
Normalized name: Bidex 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 40 mg on days 1-4 of a 4-week cycle for six cycles
Study: 34791813
Drug: DEX 40
Normalized name: Bidex 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 40 mg on days 1-4 of a 4-week cycle for six cycles with ruxolitinib 15 mg BID on days 1-21 of each cycle
Study: 33077895
Drug: Elamipretide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide (40 mg per day)
Study: 36221362
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium lactate infusion
Study: 32788268
Drug: Initial fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial fasting and intravenous fluids (control)
Study: 35251940
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus app-based intervention after the active study phase (waitlist control/TAU group)
Study: 32537847
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg on days 1 and 15 and merestinib 80 mg once daily (QD; 28-day cycle)
Study: 35138568
Drug: SRP+low‐level laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+low‐level laser therapy (LLLT) with Nd:YAG laser (group 2)
Study: 33066856
Drug: Turmacin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmacin 0.5 g
Study: 33066856
Drug: Turmacin 1
Normalized name: Turimycin A5
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmacin 1 g
Study: 33356569
Drug: Multimodal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pain regimen (pregabalin, celecoxib, acetaminophen, regional block with oxycodone for breakthrough pain)
Study: 33356569
Drug: Conventional pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pain management (regional block, acetaminophen, oxycodone)
Study: 35644038
Drug: Family based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family based treatments (FBTs)
Study: 33010766
Drug: Trochlear resurfacing
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trochlear resurfacing with HemiCAP® PF Classic implant
Study: 36175532
Drug: Modified nasopharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified nasopharyngeal oxygen therapy (Group Naso)
Study: 36175532
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (Group HFNO)
Study: 33454393
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with routine oral hygiene maintenance instructions (OHMI)
Study: 33454393
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene maintenance instructions (OHMI) alone
Study: 33761206
Drug: ALVAC-HIV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV vaccine regimen (2704 participants)
Study: 35056316
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SCS and DRGS (SCS+DRGS)
Study: 32704082
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support plus green-banana biomass (40 g) (n=21)
Study: 33400390
Drug: UC-MSC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment (100 ± 20 × 10^6 UC-MSCs, two intravenous infusions at day 0 and 3)
Study: 33400390
Drug: Control (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vehicle solution, two infusions)
Study: 35711442
Drug: bivalent Oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent Oral Poliovirus Vaccine (bOPV)
Study: 33550679
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for the TSST‐M alone
Study: 33550679
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for the TSST‐M with a parent
Study: 32114186
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment (5 worksites; n = 50 participants)
Study: 32114186
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (3 worksites; n = 47 participants)
Study: 32114186
Drug: Both enhanced
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both enhanced and minimal treatment
Study: 34337726
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg IV 30 min before surgery and then 40 mg IV every 12 h for the initial 48 h postoperatively (n=20)
Study: 33945983
Drug: Feedback-informed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback-informed treatment (FIT)
Study: 38721015
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (C)
Study: 35407572
Drug: Mosapride SR
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride SR 15 mg combined with esomeprazole 20 mg once daily (ME group)
Study: 35407572
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily alone (E group)
Study: 32062494
Drug: PG54 (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG54 (n = 434), administered prostaglandin F2α (25 mg im) 7 days prior to TAI
Study: 32062494
Drug: PG72 (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG72 (n = 426), same treatment as PG54 but TAI performed 72 ± 2 h after CIDR removal
Study: 35507901
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (NC)
Study: 37259053
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (AOM) treatment for 6 months
Study: 35897358
Drug: LLLT (Low-Level
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLLT (Low-Level Laser Therapy)
Study: 38324741
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy alone (control group)
Study: 32183897
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with awareness of the patient guideline
Study: 34800989
Drug: verum occipital
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: verum occipital tDCS treatment for 28 days
Study: 34800989
Drug: sham occipital
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham occipital tDCS treatment
Study: 32316911
Drug: Lovastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (10 to 40 mg/day)
Study: 34857640
Drug: Prophylactic dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dextrose gel
Study: 34857640
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (controls)
Study: 35966875
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg daily for 56 weeks
Study: 34609058
Drug: Sandwich osteotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich osteotomy with simultaneous implant placement using patient-specific guides (PSGs)
Study: 32239737
Drug: Nerve stimulator-guided
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator-guided injection with methylprednisolone/lidocaine
Study: 33740736
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel, applied twice weekly for 3 weeks
Study: 33740736
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing with silver sulfadiazine ointment, applied twice daily
Study: 32543876
Drug: Manual Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Physical Therapy (MPT)
Study: 32543876
Drug: Conventional Pharmacologic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Pharmacologic Treatment (CPT)
Study: 34720019
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg) tablet given twice a day for two months
Study: 33682556
Drug: ZSP1601 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 (25 to 350 mg single ascending dose)
Study: 33682556
Drug: ZSP1601 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 (50 or 100 mg QD multiple ascending doses)
Study: 33682556
Drug: ZSP1601 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 (100 mg)
Study: 32274634
Drug: GM-CSF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (2 ng/ml)
Study: 616788547
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + L-carnitine